Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1617-1624

  Gödeke, Julia ^b   Pustelny, Christian ^a   Häussler, Susanne ^a,b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYL TRANSFER RNA; AMPICILLIN; AZITHROMYCIN; BACTERIAL PROTEIN; CARBENICILLIN; PEPTIDE TRANSFER RIBONUCLEIC ACID; PEPTIDYL TRNA HYDROLASE; RHAMNOLIPID; RHLR PROTEIN; RIBONUCLEASE; TRANSFER RNA; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CELL KILLING; CODON; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIPOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RECYCLING; RNA TRANSLATION;

AZITHROMYCIN; BACTERIAL PHYSIOLOGICAL PHENOMENA; BACTERIAL PROTEINS; CARBOXYLIC ESTER HYDROLASES; CELL LINE; HUMANS; PSEUDOMONAS AERUGINOSA; RNA, TRANSFER, AMINO ACYL;

EID: 84875123406     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02582-12     Document Type: Article

References (47)

1. de Bentzmann S, Plesiat P. 2011. The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ. Microbiol. 13:1655-1665.
2. Tummler B, Bosshammer J, Breitenstein S, Brockhausen I, Gudowius P, Herrmann C, Herrmann S, Heuer T, Kubesch P, Mekus F, Romling U, Schmidt KD, Spangenberg C, Walter S. 1997. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Behring Inst. Mitt. 98:249-255.
3. Wagner VE, Iglewski BH. 2008. P. aeruginosa biofilms in CF infection. Clin. Rev. Allergy Immunol. 35:124-134.
4. Ciofu O, Mandsberg LF, Wang H, Hoiby N. 2012. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol. Med. Microbiol. 65:215-225.
5. Davies JC, Bilton D. 2009. Bugs, biofilms, and resistance in cystic fibrosis. Respir. Care 54:628-640.
6. Murray TS, Egan M, Kazmierczak BI. 2007. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19: 83-88.
7. Fothergill JL, Winstanley C, James CE. 2012. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti Infect. Ther. 10:219-235.
8. Rybtke MT, Jensen PO, Hoiby N, Givskov M, Tolker-Nielsen T, Bjarnsholt T. 2011. The implication of Pseudomonas aeruginosa biofilms in infections. Inflamm. Allergy Drug Targets 10:141-157.
9. Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M. 2010. Interference of Pseudomonas aeruginosa signalling and biofilm formation for infection control. Expert Rev. Mol. Med. 12:e11. doi:10.1017/S1462399410001420.
10. Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL. 2007. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr. Pulmonol. 42:533-541.
11. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. 2006. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61:895-902.
12. Hansen CR, Pressler T, Koch C, Hoiby N. 2005. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 4:35-40.
13. Keicho N, Kudoh S. 2002. Diffuse panbronchiolitis: role of macrolides in therapy. Am. J. Respir. Med. 1:119-131.
14. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, III. 2003. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749-1756.
15. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, Kawamoto S, Kohno S. 1995. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 50:1246-1252.
16. Steinkamp G, Schmitt-Grohe S, Doring G, Staab D, Pfrunder D, Beck G, Schubert R, Zielen S. 2008. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir. Med. 102: 1643-1653.
17. Nagata T, Mukae H, Kadota J, Hayashi T, Fujii T, Kuroki M, Shirai R, Yanagihara K, Tomono K, Koji T, Kohno S. 2004. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob. Agents Chemother. 48:2251-2259.
18. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. 2001. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45:1930-1933.
19. van Delden C, Kohler T, Brunner-Ferber F, Francois B, Carlet J, Pechere JC. 2012. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 38:1118-1125.
20. Yanagihara K, Tomono K, Imamura Y, Kaneko Y, Kuroki M, Sawai T, Miyazaki Y, Hirakata Y, Mukae H, Kadota J, Kohno S. 2002. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J. Antimicrob. Chemother. 49:867-870.
21. Yanagihara K, Tomono K, Sawai T, Kuroki M, Kaneko Y, Ohno H, Higashiyama Y, Miyazaki Y, Hirakata Y, Maesaki S, Kadota J, Tashiro T, Kohno S. 2000. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J. Antimicrob. Chemother. 46:69-72.
22. Wozniak DJ, Keyser R. 2004. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125:62-69.
23. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. 2006. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 50: 1680-1688.
24. Perez-Martinez I, Haas D. 2011. Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55:3399-3405.
25. Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M. 2008. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52:3648-3663.
26. Starosta AL, Karpenko VV, Shishkina AV, Mikolajka A, Sumbatyan NV, Schluenzen F, Korshunova GA, Bogdanov AA, Wilson DN. 2010. Interplay between the ribosomal tunnel, nascent chain, and macrolides influences drug inhibition. Chem. Biol. 17:504-514.
27. Lovmar M, Vimberg V, Lukk E, Nilsson K, Tenson T, Ehrenberg M. 2009. Cis-acting resistance peptides reveal dual ribosome inhibitory action of the macrolide josamycin. Biochimie 91:989-995.
28. Lovmar M, Tenson T, Ehrenberg M. 2004. Kinetics of macrolide action: the josamycin and erythromycin cases. J. Biol. Chem. 279:53506-53515.
29. Kossel H, RajBhandary UL. 1968. Studies on polynucleotides. LXXXVI. Enzymic hydrolysis of N-acylaminoacyl-transfer RNA. J. Mol. Biol. 35: 539-560.
30. Woodcock DM, Crowther DM, Doherty J, Jefferson S, DeCruz E, Noyer-Weidner M, Smith SS, Michael M, Graham MW. 1989. Quantitative evaluation of Escherichia coli host strains for tolerance to cytosine methylation in plasmid and phage recombinants. Nucleic Acids Res. 17: 3469-3478.
31. Qiu D, Damron FH, Mima T, Schweizer HP, Yu HD. 2008. PBAD-based shuttle vectors for functional analysis of toxic and highly regulated genes in Pseudomonas and Burkholderia spp. and other bacteria. Appl. Environ. Microbiol. 74:7422-7426.
32. Dittmar KA, Sorensen MA, Elf J, Ehrenberg M, Pan T. 2005. Selective charging of tRNA isoacceptors induced by amino-acid starvation. EMBO Rep. 6:151-157.
33. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9:671-675.
34. Kohler T, Dumas JL, Van Delden C. 2007. Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationaryphase killing of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51:4243-4248.
35. Wilhelm S, Gdynia A, Tielen P, Rosenau F, Jaeger KE. 2007. The autotransporter esterase EstA of Pseudomonas aeruginosa is required for rhamnolipid production, cell motility, and biofilm formation. J. Bacteriol. 189:6695-6703.
36. Ochsner UA, Koch AK, Fiechter A, Reiser J. 1994. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J. Bacteriol. 176:2044-2054.
37. Essar DW, Eberly L, Hadero A, Crawford IP. 1990. Identification and characterization of genes for a second anthranilate synthase in Pseudomonas aeruginosa: interchangeability of the two anthranilate synthases and evolutionary implications. J. Bacteriol. 172:884-900.
38. Haid S, Windisch MP, Bartenschlager R, Pietschmann T. 2010. Mousespecific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J. Virol. 84:964-975.
39. Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse F, Frank R, Pietschmann T. 2011. Hepatitis C virus complete life cycle screen for identification of small molecules with pro-or antiviral activity. Antiviral Res. 89:136-148.
40. Yeung AT, Torfs EC, Jamshidi F, Bains M, Wiegand I, Hancock RE, Overhage J. 2009. Swarming of Pseudomonas aeruginosa is controlled by a broad spectrum of transcriptional regulators, including MetR. J. Bacteriol. 191:5592-5602.
41. Mencarelli A, Distrutti E, Renga B, Cipriani S, Palladino G, Booth C, Tudor G, Guse JH, Hahn U, Burnet M, Fiorucci S. 2011. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. Eur. J. Pharmacol. 665:29-39.
42. Favre-Bonte S, Kohler T, Van Delden C. 2003. Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J. Antimicrob. Chemother. 52:598-604.
43. Kobayashi T, Tateda K, Matsumoto T, Miyazaki S, Watanabe A, Nukiwa T, Yamaguchi K. 2002. Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate. J. Antimicrob. Chemother. 50:59-66.
44. Gonzalez de Valdivia EI, Isaksson LA. 2004. A codon window in mRNA downstream of the initiation codon where NGG codons give strongly reduced gene expression in Escherichia coli. Nucleic Acids Res. 32:5198-5205.
45. Gonzalez de Valdivia EI, Isaksson LA. 2005. Abortive translation caused by peptidyl-tRNA drop-off at NGG codons in the early coding region of mRNA. FEBS J. 272:5306-5316.
46. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, Wu G, Villanueva J, Wei T, Ausubel FM. 2006. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc. Natl. Acad. Sci. U. S. A. 103:2833-2838.
47. West SE, Schweizer HP, Dall C, Sample AK, Runyen-Janecky LJ. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86.